Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: A phase II study

Breast Cancer Research and Treatment

Volumn 79, Issue 3, 2003, Pages 391-397

  Burstein, Harold J ^a,b   Demetri, George D ^a,b   Mueller, Elisabetta ^a   Sarraf, Pasha ^a   Spiegelman, Bruce M ^a   Winer, Eric P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Breast cancer clinical trials; Peroxisome proliferator activated receptor (PPAR); Thiazolidinediones; Troglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 27-29 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; HEMOGLOBIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; TROGLITAZONE; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DYSPEPSIA; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSOMNIA; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WOUND INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMANS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER; MIDDLE AGED; NEOPLASM INVASIVENESS; THIAZOLES; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 0037899628     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024038127156     Document Type: Article

References (22)

1. Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405: 421-425, 2000
2. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53: 409-435, 2002
3. Parulkar AA, Pendergraass ML, Granda-Ayala R, Lee TR, Fonseca VA: Nonhypoglycemic effects of thiazolidinedionies. Ann Int Med 134: 61-71, 2001
4. Spiegelman BM: PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514, 1998
5. Willson TM, Cobb JE, Cowan DJ et al.: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39: 665-668, 1996
6. Spiegelman BM, Flier JS: Adipogenesis and obesity: rounding out the big picture. Cell 87: 377-389, 1996
7. Demetri GD, Fletcher CDM, Mueller E et al.: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci 96: 3951-3956, 1999
8. Demetri GD, Spiegelman B, Fletcher CD et al.: Differentiation of liposarcomas in patients treated with PPAR γ ligand troglitazone: documentation of biological activity in myxoid/round cell and pleomorphic subtypes. Proc Am Soc Clin Oncol 18: 535a, 1999 (abstract 2064)
9. Seed B: PPARγ and colorectal carcinoma: conflicts in a nuclear family. Nat Med 4: 1004-1005, 1998
10. Kubota T, Koshizuka K, Williamson EA et al.: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998
11. Mueller E, Smith M, Sarraf P et al.: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci 97: 10990-10995, 2000
12. Mueller E, Sarraf P, Tontonoz P et al.: Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1: 465-470, 1998
13. Yin F, Wakino S, Liu Z et al.: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286: 916-922, 2001
14. Elstner E, Muller C, Koshizuka K et al.: Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci 95: 8806-8811, 1998
15. Mehta RG, Williamson E, Patel MK, Koeffler HP: A ligand of peroxisome proliferator-activated receptor g, retinoids, and prevention of preneoplastic mammary lesions. J Natl Cancer Inst 92: 418-423, 2000
16. Suh N, Wang Y, Williams CR et al.: A new ligand for the peroxisome proliferator-activated receptor-γ (PPAR-γ), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59: 5671-5673, 1999
17. Spencer CM, Markham A: Troglitazone. Drugs 54: 89-101, 1997
18. Gale EAM: Lessons from the glitazones: a story of drug development. Lancet 357: 1870-1875, 2001
19. Esteva FJ, Glaspy JA, Baidas SM et al.: Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 21: 51a, 2002 (abstract 203)
20. Pignatelli M, Cortes-Canteli M, Lai C, Santos A, Perez-Castillo A: Peroxisome proliferator-activated receptor γ is an inhibitor of erbBs activity in human breast cancer cells. J Cell Sci 114: 4117-4126, 2001
21. Rubin GL, Zhao Y, Kalus AM, Simpson ER: Peroxisome proliferator-activated receptor g ligands inhibit estrogen bio-synthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60: 1604-1608, 2000
22. Girnun GD, Smith WM, Drori S et al.: APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci USA 99: 13771-13776, 2002